Hypothermic oxygenated machine perfusion (HOPE) has recently emerged as a preservation technique which can facilitate reduced ischemic injury and improve clinical outcomes following liver transplantation. First developed with the advent solid organ transplantation, hypothermic machine perfusion largely fell out of favour following the discovery of preservation solutions which can satisfactorily preserve grafts with the ease and relative efficacy of static cold storage (SCS). However, with an increasing need to develop techniques to reduce graft injury and better utilise marginal or DCD grafts, HOPE has emerged as a relatively simple, safe, and efficacious technique to optimise clinical outcomes following liver transplantation. Perfusing the graft with cold, acellular, oxygenated perfusate either via the portal vein (PV) alone, or via both the PV and hepatic artery (HA), HOPE is generally commenced for a period of at least 1-2 hours immediately prior to implantation. The technique has recently been validated by multiple randomised control trials, and pre-clinical evidence suggests HOPE primarily reduces graft injury by reducing the accumulation of harmful mitochondrial intermediates, and subsequently, the severity of post-reperfusion injury. HOPE can also facilitate dynamic graft assessment, most notably via the measurement of flavin mononucleotide in the perfusate, allowing transplant teams to make better informed clinical decisions prior to transplantation and may provide a platform to administer novel therapeutic agents to ex situ organs. As such, HOPE is uniquely positioned to revolutionise how liver transplantation is approached and facilitate optimised clinical outcomes for liver transplant recipients.